FDA Advisory Committee Votes to Recommend Additional Data for Sintilimab Submission

/PRNewswire/ -- The U.S. Food and Drug Administration (FDA) held a public Oncology Drug Advisory Committee (ODAC) for sintilimab, which is under review for the...

Related Keywords

China ,Taiwan ,United States ,Hong Kong ,Suzhou ,Jiangsu ,Macau ,American ,Innovent Biologics ,Adimab Incyte ,Yongjun Liu ,Eli Lilly ,Jacob Van Naarden ,Oncology Drug Advisory Committee ,Drug Administration ,Md Anderson Cancer Center ,National Reimbursement Drug List ,International Agency For Research On Cancer ,American Cancer Society ,Incyte Corporation ,Radiographic Review Committee ,Independent Radiographic Review Committee ,Main Board ,Stock Exchange ,Hong Kong Limited ,Cancer Center ,Mainland China ,International Agency ,Cancer Fact ,Accessed January ,American Cancer ,Key Statistics ,Non Small Cell Lung Cancer ,Pharmaceuticals ,Medical Pharmaceuticals ,Health Care Amp Hospitals ,Fda Approval ,